Back to Agenda
Informing Development and Authorizations Using Real World Evidence/Artificial Intelligence
Session Chair(s)
Lawrence Eugene Liberti, RAC
Director, D.K. Kim International Center for Regulatory Science, The Kim Center/ USC DRQS, United States
The evolution of actionable insights on how medicines are used, generated from real world evidence and artificial intelligence will be discussed. This session will focus on knowledge management, regulatory intelligence, and learning healthcare systems.
Learning Objective : Discuss the potential for artifical intelligence and real world evidence to inform both development and authorization; Identify the opportunities and barriers and how AI and RWE in conjunction with knowledge management can enable better development and regulatory decisions.
Speaker(s)
Magda Bujar, PhD, MSc
Associate Director, Regulatory Programme and Strategic Partnerships, Centre for Innovation in Regulatory Science (CIRS), United Kingdom
How Do Companies View Knowledge Management as a Decision-Making Tool?
Andrea Julsing Keyter, MS
Deputy Director, Medical Devices, South African Health Products Regulatory Authority, South Africa
Learning Healthcare Systems: Managing Real World Evidence/Knowledge - How Can This Transition Healthcare Data to Actionable Information?
Mukesh Singhal, MBA
Partner, Deloitte, United States
Potential Uses of AI for Regulatory Intelligence: How Can This be Used Practically and What are the Barriers and Opportunities?
Have an account?